Evaluation of a novel particle-based assay for detecting SLE-related autoantibodies.
Anti-Sm autoantibodies
Anti-ribosomal-
Chemiluminescence assays
Clinical SLEDAI-2K
Particle-based multi-analyte technology
SLE clinical manifestations
SLEDAI-2K
Systemic lupus erythematosus
anti-dsDNA autoantibodies
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
30 May 2024
30 May 2024
Historique:
received:
06
02
2024
revised:
18
04
2024
accepted:
04
05
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
Anti-dsDNA, anti-Sm, and anti-ribosomal-P autoantibodies are hallmarks of systemic lupus erythematosus (SLE), being anti-dsDNA and anti-Sm included in 2019-ACR/EULAR SLE-Classification Criteria. Enzyme-linked (ELISA) and chemiluminescence assays (CIA) are widely established in immunology laboratories, but new technologies, such as particle-based multi-analyte technology (PMAT), are nowadays available. The present study aimed to compare the presence of anti-dsDNA and anti-Sm autoantibodies measured by CIA and PMAT and analyze diagnostic and clinical SLE activity performance. Anti-ribosomal-P autoantibodies by PMAT were also included. Consequently, anti-dsDNA and anti-Sm detected by CIA showed substantial agreement with PMAT (Cohen's
Identifiants
pubmed: 38778929
doi: 10.1016/j.heliyon.2024.e30767
pii: S2405-8440(24)06798-7
pmc: PMC11108844
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e30767Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.